Therapy News and Research

RSS

Leadless pacemaker technology shows promising performance after 12 months

Vivek Reddy, MD, Director of Arrhythmia Services for The Mount Sinai Hospital, reported his promising12-month follow-up data showing the world's first leadless pacemaker is demonstrating overall device performance comparable to conventional pacemakers. Dr. Reddy presented the one-year LEADLESS study data findings during his late-breaking clinical trial presentation on May 9 at Heart Rhythm 2014, the Heart Rhythm Society's 35th Annual Scientific Sessions in San Francisco, CA.

12 May 2014

Akebia Therapeutics reports net loss of $9.7 million for Q1 2014

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced financial results for the first quarter ended March 31, 2014.

12 May 2014

NSHOA and Caris Life Sciences collaborate to establish personalized cancer care program

North Shore Hematology Oncology Associates and Caris Life Sciences today announced a collaboration to establish a personalized cancer care program for patients in the greater Long Island area.

12 May 2014

Jintronix receives clearance from FDA for Jintronix rehabilitation system

Jintronix, a company radically changing how patients rehabilitate from stroke or other injury, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Jintronix rehabilitation system.

12 May 2014

Molecular imaging and multimodality: an interview with Professor Silvio Aime, University of Turin

Molecular imaging aims at the visualization of molecules or molecular events that occur at the cellular level. Clearly it also allows the possibility of looking inside the biochemical pathway at the cellular level and therefore enables us to look at the onset of diseases well before they are resolved into structural change.

From Bruker BioSpin Division 12 May 2014

Researchers reveal how protein acts as brake against pathological growth of heart muscle

Cardiovascular disease remains the number one cause of death in the Western world, with heart failure representing the fastest-growing subclass over the past decade.

12 May 2014

Coronary artery calcium score may help guide aspirin therapy, finds new research

For over 30 years, aspirin has been known to prevent heart attacks and strokes, but who exactly should take a daily aspirin remains unclear. New research published today in Circulation: Cardiovascular Quality and Outcomes shows that your coronary artery calcium (CAC) score, a measurement of plaque in the arteries that feed the heart, may help determine whether or not you are a good candidate for aspirin.

12 May 2014

Treating ADHD with stimulant medication may reduce smoking risk

Treating attention deficit hyperactivity disorder (ADHD) with stimulant medication may reduce smoking risk, especially when medication is taken consistently, according to an analysis led by researchers at Duke Medicine.

12 May 2014

AFib patients who are on blood thinning medications are at higher risk of developing dementia

A new study by researchers at the Intermountain Medical Center Heart Institute in Salt Lake City has found that atrial fibrillation patients who are on blood thinning medications are at higher risk of developing dementia if their doses are not in the optimal recommended range.

12 May 2014

Flatiron Health agrees to acquire Altos Solutions

Altos Solutions, creators of OncoEMR, the first web-based oncology-specific electronic medical record, today announced an agreement to be acquired by Flatiron Health.

9 May 2014

Antares Pharma reports total revenues of $5.2 million for first quarter 2014

Antares Pharma, Inc. today reported operating and financial results for the first quarter ended March 31, 2014.

9 May 2014

Experimental antibody temporarily halts progression of neuroblastoma in children

Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital.

9 May 2014

Scientists decrypt interaction network of hepatitis C virus proteins in living human cells

Scientists at the Helmholtz Zentrum München have for the first time decrypted the interaction network of hepatitis C virus proteins in living human cells. Their findings will contribute to a better understanding of the mechanisms behind inflammatory liver disease caused by hepatitis C viruses and open up new avenues for therapy development.

9 May 2014

AbbVie seeks marketing approval from EMA for all-oral, interferon-free therapy to treat HCV infection

AbbVie submitted marketing authorization applications (MAAs) to the European Medicines Agency seeking approval for the company’s investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection.

9 May 2014

Comer Children's Hospital offers high-dose radiation therapy for relapsed neuroblastoma

The University of Chicago Medicine Comer Children's Hospital has become the first in Illinois to offer pioneering, targeted, high-dose, intravenous radiation therapy for relapsed neuroblastoma and other difficult-to-treat cancers.

9 May 2014

EXCEMED meeting draws experts to explore roles of genetics, environment in MS pathology

The diagnosis and treatment of Multiple Sclerosis (MS) have dramatically improved over recent decades due to scientific advancements, yet MS persists as one of the most disabling neurological disorders, having a significant impact on young adults - the age group most affected by the disease.

9 May 2014

Patients with Parkinson's disease show improvements after exenatide therapy

Follow-Up Study Published in the Journal of Parkinson's Disease Supports an Earlier "Proof of Concept" Trial. A follow-up study of patients with Parkinson's disease (PD) who participated in an earlier "proof of concept" clinical trial using exenatide showed that improvements persisted twelve months after discontinuing exenatide therapy.

9 May 2014

Therapy News and Research

Leadless pacemaker technology shows promising performance after 12 months

Akebia Therapeutics reports net loss of $9.7 million for Q1 2014

NSHOA and Caris Life Sciences collaborate to establish personalized cancer care program

Jintronix receives clearance from FDA for Jintronix rehabilitation system

Molecular imaging and multimodality: an interview with Professor Silvio Aime, University of Turin

Researchers reveal how protein acts as brake against pathological growth of heart muscle

Coronary artery calcium score may help guide aspirin therapy, finds new research

Treating ADHD with stimulant medication may reduce smoking risk

AFib patients who are on blood thinning medications are at higher risk of developing dementia

Flatiron Health agrees to acquire Altos Solutions

Antares Pharma reports total revenues of $5.2 million for first quarter 2014

Experimental antibody temporarily halts progression of neuroblastoma in children

Scientists decrypt interaction network of hepatitis C virus proteins in living human cells

AbbVie seeks marketing approval from EMA for all-oral, interferon-free therapy to treat HCV infection

Comer Children's Hospital offers high-dose radiation therapy for relapsed neuroblastoma

EXCEMED meeting draws experts to explore roles of genetics, environment in MS pathology

Patients with Parkinson's disease show improvements after exenatide therapy

Researchers discover new mechanism that distinguishes normal blood stem cells from blood cancers

Wake Forest Baptist Medical Center finds novel treatment to keep lung cancer at bay

Clovis Oncology reports net loss of $30.7 million for first quarter 2014

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News